Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Scientists have long known that TFEB is a key regulator of the cell's recycling system, but it's been nearly impossible to target with drugs—until now. A new Nature study from TIGEM researchers has mapped a molecular pathway (TBK1/ULK1) that switches TFEB on, revealing fresh drug targets for lysosomal diseases, neurodegeneration, and cancer. This could finally bridge the gap between decades of lab discoveries and real-world therapies.
Lysosomes are the cell's recycling centers, and when they malfunction, toxic waste builds up—driving rare genetic diseases, neurodegenerative conditions, and certain cancers. For over 15 years, scientists have eyed TFEB, the master regulator of lysosomal function, as a prime therapeutic target. The catch? Transcription factors like TFEB are notoriously hard to drug directly.
A new study published in Nature by researchers at Italy's Telethon Institute of Genetics and Medicine (TIGEM) has found a workaround. Rather than targeting TFEB itself, the team identified the upstream molecular machinery that activates it: a signaling axis involving enzymes TBK1 and ULK1. When lysosomes are under stress, these enzymes modify a protein called FNIP1, triggering TFEB to enter the nucleus and fire up cellular recycling genes. The researchers also linked this pathway to follicular lymphoma, where mutations in a lysosomal pump component lead to persistent TFEB activation—helping tumor cells survive in nutrient-poor conditions.
Key Takeaways:
Why it matters: By pinpointing druggable regulators upstream of TFEB, this research opens practical new routes to therapies for a wide range of diseases where cellular waste clearance goes wrong.
